about
sameAs
Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancerAssociation between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer.Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the PopulationGenome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer TypesPALB2, CHEK2 and ATM rare variants and cancer risk: data from COGSAssessing the genetic architecture of epithelial ovarian cancer histological subtypes.Assessment of Multifactor Gene-Environment Interactions and Ovarian Cancer Risk: Candidate Genes, Obesity, and Hormone-Related Risk Factors.Unravelling in vitro variables of major importance for the outcome of mass spectrometry-based serum proteomics.Markers aiding the diagnosis of chondroid tumors: an immunohistochemical study including osteonectin, bcl-2, cox-2, actin, calponin, D2-40 (podoplanin), mdm-2, CD117 (c-kit), and YKL-40.Association between common germline genetic variation in 94 candidate genes or regions and risks of invasive epithelial ovarian cancerHormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium studymiR-345 in metastatic colorectal cancer: a non-invasive biomarker for clinical outcome in non-KRAS mutant patients treated with 3rd line cetuximab and irinotecan.Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA.Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer: a report from the Ovarian Cancer Association Consortium.Estrogen receptor beta rs1271572 polymorphism and invasive ovarian carcinoma risk: pooled analysis within the Ovarian Cancer Association Consortium.miR-21 Expression in Cancer Cells may Not Predict Resistance to Adjuvant Trastuzumab in Primary Breast Cancer.Common alleles in candidate susceptibility genes associated with risk and development of epithelial ovarian cancer.Circulating antinuclear antibodies in patients with pelvic masses are associated with malignancy and decreased survivalA highly sensitive quantitative real-time PCR assay for determination of mutant JAK2 exon 12 allele burdenTubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies.Consortium analysis of gene and gene-folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk.Tissue microRNAs as predictors of outcome in patients with metastatic colorectal cancer treated with first line Capecitabine and Oxaliplatin with or without Bevacizumab.Human papillomavirus in head and neck squamous cell carcinoma of unknown primary is a common event and a strong predictor of survival.Genetic variation in TYMS in the one-carbon transfer pathway is associated with ovarian carcinoma types in the Ovarian Cancer Association ConsortiumRecent alcohol consumption and risk of incident ovarian carcinoma: a pooled analysis of 5,342 cases and 10,358 controls from the Ovarian Cancer Association Consortium.Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study.CT versus FDG-PET/CT response evaluation in patients with metastatic colorectal cancer treated with irinotecan and cetuximab.The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testingGermline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancerAssessment of hepatocyte growth factor in ovarian cancer mortality.Prostate cancer susceptibility polymorphism rs2660753 is not associated with invasive ovarian cancerMicroRNA Expression in Formalin-fixed Paraffin-embedded Cancer Tissue: Identifying Reference MicroRNAs and Variability.Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium.Shared genetics underlying epidemiological association between endometriosis and ovarian cancer.Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus.Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium.(GT)n Repeat Polymorphism in Heme Oxygenase-1 (HO-1) Correlates with Clinical Outcome after Myeloablative or Nonmyeloablative Allogeneic Hematopoietic Cell TransplantationTopoisomerase I copy number alterations as biomarker for irinotecan efficacy in metastatic colorectal cancer.Clinical validation of chemotherapy predictors developed on global microRNA expression in the NCI60 cell line panel tested in ovarian cancer.Epidermal growth factor receptor exon 20 p.S768I mutation in non-small cell lung carcinoma: A case report combined with a review of the literature and investigation of clinical significance
P50
Q24633316-8D175DF4-EDB4-4D2B-9EFD-526B11D69E29Q27851709-74576319-2A3C-4D9F-B7C4-0AE96BA3FC5FQ28266112-DEE97482-6A67-47E3-8387-8805272E8487Q28388497-BB83B7FA-2497-49DC-84CB-6338C2D5FE5AQ28584533-E348B42A-D9DD-4403-B86F-6DD47C09EFBAQ30276986-BE7C4B15-3B71-4428-A8B4-6C893C309EBDQ30277151-23892ADF-5F16-45D9-9DF9-53924768F8BEQ33263988-A96BC21D-E1F1-4A9F-84CB-B8515F59E27BQ33273451-4EF076A8-8F78-461E-86EE-24A35F2B17D7Q33471495-2E051E05-DCD7-45E3-A4BA-0D0C709A08C3Q33551425-E7DA3F4B-0FD6-4F96-87E3-D8FD51798D4EQ33773806-445B56E8-5FF5-4691-80C8-17C2C492E8A7Q33778612-3D11EDB4-9578-4AAA-9978-D72FD9B60262Q33921008-A749C3C4-A93B-4D04-B62B-73F54A78D286Q33932856-9BA23E88-F1E6-4A8A-8FB9-A63CB8EAAA99Q34048535-B311D291-023F-4052-B472-E9F9CFACE842Q34126314-89D2ED5A-8A7A-4ED8-81F9-7A0A145E29FFQ34170421-7B7E4C5F-A3D6-4005-ADED-7C40DCF4A159Q34189794-1C19AA87-93B4-474B-BAFD-511633F71655Q34338047-5AB7AB96-513B-4BE2-899D-76260453B76DQ34342248-C2A2E36D-0DD9-4CB8-B02B-44552ECDFCD7Q34343614-F20D3FD4-F7F9-4570-8365-B74ACDB766A0Q34450121-0A205DDD-E188-4D7E-9FCD-9B376332082DQ34453723-22874305-3BDA-4DE2-BF7A-F357B603BD3EQ34557167-084A83E0-7AEF-4034-93A5-1C602BFD09E7Q34687073-747F36B1-7B16-4DA5-B731-D36009B0D7A6Q34998534-56CB6292-2041-434D-8ECF-8B6AE79E7E74Q35024008-7B19A6B6-977E-42B1-A4EE-ADE4FA11DA47Q35114576-2BE215E5-57A7-4891-B606-34BE8BE191F8Q35156876-AE82907B-EFCD-43AE-8365-80DCDEF17487Q35223068-A2451EC9-6AF5-4B6A-B1A4-23D8CDFFF858Q35880960-E6200DE6-A3DF-4187-9DE2-FDD932BAC384Q36027025-9309B67F-79BC-4520-B921-94793003A7F7Q36089391-9FD34E4E-5565-40C9-B4D9-FC280685DA1AQ36124728-2A9916C5-B7F0-4B5D-897B-97CF577E8A9FQ36218993-DFC11DCD-7E96-4402-BF8A-042F690F7A95Q36229571-BB22E8E7-68B0-45C7-8ADD-F16D2D34AEC9Q36246729-4E7D8D0E-FF70-4A99-9313-AFD1D263CC85Q36320168-28E64CC9-E158-43CC-9209-3E155ED1F2FEQ36503084-92160910-A134-4942-AE41-8A83C5181BD0
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Estrid Høgdall
@ast
Estrid Høgdall
@en
Estrid Høgdall
@es
Estrid Høgdall
@nl
Estrid Høgdall
@sl
type
label
Estrid Høgdall
@ast
Estrid Høgdall
@en
Estrid Høgdall
@es
Estrid Høgdall
@nl
Estrid Høgdall
@sl
altLabel
Estrid Hogdall
@en
prefLabel
Estrid Høgdall
@ast
Estrid Høgdall
@en
Estrid Høgdall
@es
Estrid Høgdall
@nl
Estrid Høgdall
@sl
P106
P21
P31
P496
0000-0003-4689-5658